/script>
CSIR Developed Anti-Diabetes Medicine.
Dec. 7, 2019

The diabetic population in the country is close to hitting the alarming mark of 69.9 million by 2025, which denotes that the country is expected to witness an increase of 266%.

Council of Scientific and Industrial Research (CSIR), through its constituent laboratories namely CSIR-Central Institute of Medicinal & Aromatic Plants (CSIR-CIMAP), Lucknow; and CSIR-National Botanical Research Institute (CSIR-NBRI), Lucknow developed scientifically validated herbal product NBRMAP-DB as anti-diabetic formulation and the know-how for the product was licensed to M/s AIMIL Pharma Ltd., Delhi who are manufacturing and marketing it as BGR-34, across the country.

M/s AIMIL Pharmaceuticals, the licensee carried out the clinical study of BGR-34 and the trial was registered in the clinical trial registry of India (Registration number: CTRI/2016/11/007476).

Further, the formulation has shown therapeutic efficacy for treating newly diagnosed type 2 diabetes, as found in independent clinical trials conducted at Banaras Hindu University (BHU), Varanasi.

Source : PIB